Sorafenib

Comparative Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-analysis

Comparative Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-analysis

[Oncotargets and Therapy] This research evaluates the comparative efficacy and safety of axitinib and sorafenib for the treatment of metastatic renal cell carcinoma.

Useful markers predict response to chemotherapy in patients with liver cancer

By

Liver tumor cells do not respond to sorafenib if they have a less differentiated phenotype, known as the mesenchymal type, and express CD44, according to a new study.

FDA expands sorafenib approval for common thyroid cancer

FDA expands sorafenib approval for common thyroid cancer

When tumor stops responding to U.S. Food and Drug Administration approval for the anti-cancer drug sorafenib (Nexavar) has been expanded to include late-stage differentiated thyroid cancer, the most common type of thyroid cancer.

Sorafenib stopped tumor growth in patients with advanced differentiated thyroid cancer

By

The kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay nearly twice as long as placebo, according to the results of the randomized phase III trial known as DECISION.

ASCO: Sorafenib betters thyroid cancer survival

ASCO: Sorafenib betters thyroid cancer survival

Sorafenib improves survival in patients whose cancer is resistant to radioactive iodine treatment.

Radiosensitivity: A new focus on cardiovascular sequelae

Radiosensitivity: A new focus on cardiovascular sequelae

By

An increased risk of coronary artery stenosis in cancer survivors may be a long-term posttreatment effect of chest radiotherapy.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs